THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International, Inc. (TSOI) has announced new data and filing with the FDA for Orphan Drug Designation of its JadiCell adult stem cell in the treatment of Frontotemporal Dementia, a neurodegenerative disease that is the leading cause of dementia in patients under 60 years old. No therapies have been shown to reduce its progression. The JadiCell cell therapy product has previously been successful in treating patients with chronic traumatic encephalopathy (CTE) and recent data suggests the possibility of utilizing these cells in Frontotemporal Dementia.

Therapeutic Solutions International (TSOI) has filed for Orphan Drug Designation for its JadiCell Adult Stem Cell Product to treat Acute Respiratory Distress Syndrome (ARDS). The company aims to leverage existing clinical data and Phase III clearance to accelerate the treatment of this fatal lung condition.

Therapeutic Solutions International (TSOI) has created CTE Biologics, Inc. as a subsidiary company to commercialize the JadiCell stem cell platform for treating chronic traumatic encephalopathy (CTE). The company has licensed the JadiCell for this indication and is addressing FDA questions before initiating clinical trials.

Therapeutic Solutions International's spin-off company, Res Nova Bio, successfully delivers cancer-killing virus to breast cancer, causing tumor shrinkage and generating immunity.

Clinical stage biotech company Res Nova Bio has partnered with compounding pharmacy Cure Stat Rx to manufacture doses of FloraStilbene™ for a Phase I/II clinical trial in advanced breast cancer patients. The trial aims to assess the drug candidate's immunomodulatory activity. Cure Stat Rx President Ramesh Chigurupati has joined Res Nova's Advisory Board. The collaboration is based on the preclinical and pilot clinical data that supports FloraStilbene as an immune enhancer and natural killer cell activity stimulator in advanced cancer patients.

Therapeutic Solutions International (TSOI) has filed a new Phase III clinical trial application with the FDA for the use of its JadiCell adult stem cells in the treatment of acute respiratory distress syndrome (ARDS). The decision to accelerate development of the ARDS program was influenced by a recent patent victory and positive results from the Phase III clinical trial in COVID-19 associated ARDS.

Therapeutic Solutions International (TSOI) announced new findings from its spin-off, Campbell Neurosciences, revealing that CampbellCell universal donor stem cells help alleviate schizophrenia symptoms in animal models by enhancing immune modulation and boosting brain-derived neurotrophic factors (BDNF). The research indicated increased interleukin-4 production, which helps counter inflammatory cytokines like interleukin-17. Dr. Thomas Ichim highlighted the ongoing development of a biomarker for suicidal ideations, while Timothy Dixon praised the innovative approach combining immunotherapy and regenerative medicine for mental health treatment.

Therapeutic Solutions International (OTC-PINK:TSOI) announced the appointment of Thomas Ichim, Ph.D. as CEO of its spin-off, Campbell Neurosciences. Dr. Ichim, previously CEO of Medistem Inc., replaces founder Kalina O’Connor, who becomes Chief Visionary Officer. The company focuses on scientifically validating suicide as a disease with biological roots. Dr. Ichim emphasized the urgency of their mission, noting a suicide occurs every five minutes. Campbell Neurosciences aims to develop biological diagnostics and treatments for mental health conditions.